SCM
JBIO

Silverarc Capital Management’s Jade Biosciences JBIO Stock Holding History

Silverarc Capital Management’s Portfolio JBIO Stock Details JBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-2,857
Closed -$1.36M – 73
2023
Q3 		$1.36M Buy
+2,857
New +$1.55M 0.41% 53
2023
Q1 		– Sell
-1,054
Closed -$1.08M – 77
2022
Q4 		$1.08M Buy
+1,054
New +$765K 0.31% 68

Other funds holding JBIO

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Silverarc Capital Management's JBIO Position: Q4 2023 in Review

Silverarc Capital Management sold out of Jade Biosciences (JBIO) in Q4 2023, closing a stake of 2,857 shares — an estimated $1.36M sold.

Silverarc Capital Management first reported a position in JBIO in Q4 2022 and held it in 2 quarters. The position peaked at $1.36M in Q3 2023. 64 funds tracked by Wall St. Rank hold JBIO as of Q4 2023.

  • Silverarc Capital Management reported no remaining Jade Biosciences position as of Q4 2023 after selling out during the quarter.
  • Silverarc Capital Management sold 2,857 Jade Biosciences shares in Q4 2023, an estimated $1.36M.
  • Silverarc Capital Management first reported a position in Jade Biosciences in Q4 2022 and held it in 2 quarters.
  • Silverarc Capital Management's Jade Biosciences position peaked at $1.36M in Q3 2023.
  • 64 funds tracked by Wall St. Rank held Jade Biosciences as of Q4 2023.

Based on Silverarc Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.